Form 4: Alaunos Therapeutics Officer Acquires Stock Options

Sentiment:

SEC Form 4 Filing


Melinda Lackey, Legal & Administration Officer at Alaunos Therapeutics, acquired stock options on August 14, 2024.

Summary

  • Melinda Lackey, an officer at Alaunos Therapeutics, Inc., filed a Form 4 indicating a change in beneficial ownership.
  • On August 14, 2024, Lackey acquired 1,500 employee stock options with an exercise price of $2.42.
  • These options vest in equal quarterly installments starting November 14, 2024, and expire on August 13, 2034.
  • Following the transaction, Lackey directly owns 1,500 derivative securities.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of compliance for company insiders and provide transparency into their transactions in the company's securities. This filing indicates an officer's acquisition of stock options, which is a common form of compensation.

Stakeholder Impact

  • The acquisition of stock options by an officer aligns her interests with those of the shareholders, potentially incentivizing her to work towards increasing shareholder value.

Key Dates

DateDescription
08/14/2024Date of earliest transaction: acquisition of stock options.
08/14/2024Date of grant of employee stock options.
11/14/2024First vesting date for the acquired stock options.
08/13/2034Expiration date of the acquired stock options.
08/16/2024Date of signature on the Form 4 filing.

Keywords

Form 4, Stock Options, Beneficial Ownership, Alaunos Therapeutics, TCRT, Melinda Lackey, Officer

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.